- Home
- RDAC vs CUE Comparison
RDAC vs CUE Comparison
Compare RDAC & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDAC
- CUE
- Stock Information
- Founded
- RDAC 2024
- CUE 2014
- Country
- RDAC China
- CUE United States
- Employees
- RDAC N/A
- CUE N/A
- Industry
- RDAC
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- RDAC
- CUE Health Care
- Exchange
- RDAC NYSE
- CUE Nasdaq
- Market Cap
- RDAC 75.2M
- CUE 77.3M
- IPO Year
- RDAC 2024
- CUE 2018
- Fundamental
- Price
- RDAC $10.05
- CUE $1.31
- Analyst Decision
- RDAC
- CUE Strong Buy
- Analyst Count
- RDAC 0
- CUE 5
- Target Price
- RDAC N/A
- CUE $5.00
- AVG Volume (30 Days)
- RDAC 1.4K
- CUE 406.9K
- Earning Date
- RDAC 01-01-0001
- CUE 03-10-2025
- Dividend Yield
- RDAC N/A
- CUE N/A
- EPS Growth
- RDAC N/A
- CUE N/A
- EPS
- RDAC N/A
- CUE N/A
- Revenue
- RDAC N/A
- CUE $9,532,000.00
- Revenue This Year
- RDAC N/A
- CUE $73.11
- Revenue Next Year
- RDAC N/A
- CUE $11.02
- P/E Ratio
- RDAC N/A
- CUE N/A
- Revenue Growth
- RDAC N/A
- CUE 149.53
- 52 Week Low
- RDAC $10.19
- CUE $0.45
- 52 Week High
- RDAC $10.31
- CUE $2.93
- Technical
- Relative Strength Index (RSI)
- RDAC N/A
- CUE 52.47
- Support Level
- RDAC N/A
- CUE $1.21
- Resistance Level
- RDAC N/A
- CUE $1.75
- Average True Range (ATR)
- RDAC 0.00
- CUE 0.18
- MACD
- RDAC 0.00
- CUE 0.00
- Stochastic Oscillator
- RDAC 0.00
- CUE 45.00
About RDAC RISING DRAGON ACQUISITION CORP
Rising Dragon Acquisition Corp is a blank check company.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.